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sible, country profiles where BIOSIM-EPO have taken market shares. Methods: 
Countries inclusion criteria: legal definition and regulatory framework for biosimi-
lars close to the EU ones; at least 3 years of experience with BIOSIM-EPO in 2012; 
national biological market value higher than US$ 2.5 billion. Factors evaluated: 
national EPO market sizes, EPO retail/hospital distribution mixes, existence of policy 
incentives that promote BIOSIM-EPO prescriptions or substitution and BIOSIM-EPO 
prices relative to reference EPO. Data on medicine volumes, values and ex-manu-
facturer prices for all EPOs (alfa, BIOSIM-EPO (EPO alfa biosimilar), beta and second-
generation ones) were provided by IMS Health. Volumes were calculated in DDD 
(Defined Daily Doses) and prices in euros per DDD. Data were available from 2007 
until 2012. Results: EU-5 and Japan have been included. Germany: small-sized 
market, dominant retail market distribution, incentives to prescribe BIOSIM-EPO 
(quotas) and to substitute patented for ‘bioidenticals’ EPO, high BIOSIM-EPO uptakes 
(30.4% in 2012). Spain and Italy: medium-sized markets, dominant hospital distri-
bution, no incentives, 11.5% and 8.6% BIOSIM-EPO uptakes respectively. Japan: the 
largest market, mixed distribution channels, no incentives, 6.8% BIOSIM-EPO uptake. 
France: large-sized market, dominant retail market distribution, no incentives, 5.8% 
BIOSIM-EPO uptake. The UK: the smallest market, mixed distribution channels, no 
incentives, 2.0% BIOSIM-EPO uptake. The price differences between BIOSIM-EPO 
and their reference play no role at a global level (e.g. -10.8% in Germany and -26.9% 
in Japan). ConClusions: This study proved that EPO markets are highly country 
specific. There is no single specific profile for countries in which BIOSIM-EPO have 
significantly penetrated the market. Providing national prescription and substitu-
tion incentives is the only determining factor for BIOSIM-EPO uptakes. National EPO 
market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO prices relative 
to reference EPO are not significant factors.
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objeCtives: With a total volume of € 24 billion a year, Japan is the world’s second 
largest medical device market behind the US. It imports about 35% of the medical 
devices from abroad. Although imports have been increasing steadily over the 
past years, Japan still struggles to have similar access to advanced medical 
devices as the US and Europe. This research aimed to have a closer look at the 
Japanese medical device market, and further explore access barriers. Methods: 
This research was conducted through in-depth secondary research and inter-
views with a variety of stakeholders including payers, academics, and KOLs in 
Japan. Results: Unlike most markets where an FDA or CE mark is sufficient, 
medical devices in Japan require a separate in-country regulatory approval before 
reimbursement. Not only is this process long (approximately 2.2 years) but the 
requirements are much more stringent compared to the US or EU, often requiring 
local clinical data. This has resulted in many large med-tech companies staying 
away from the Japanese market. ConClusions: It is important for foreign manu-
facturers to understand the implications of the Japanese regulatory barriers and 
address them in their foreign market strategies allowing them to assess product 
viability early on.
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objeCtives: Concerns due to external reference pricing (ERP) have been expressed 
by industry regarding spill-over effects. It is also often argued that ERP can lead 
to a downward price convergence. The objective of this project was to gain bet-
ter understanding of price dynamics of ERP-based systems using a simulation 
model. Methods: A simulation model (developed for the EU Commission) was 
built to simulate the impact of ERP as main criterion to set drug price across 
28 European Union Member States, Iceland, Norway and Switzerland. Base case 
scenario simulated ERP price for a fictitious drug based on real ERP characteris-
tics. Twenty fictitious scenarios simulated ERP price when introducing changes 
in ERP characteristics and/or exogenous effects such as genericisation, changes 
in exchange rates, price cuts. These scenarios were chosen based on the potential 
rapid and important price erosion attributed to ERP. Impacts of these scenarios 
were classified depending on changes in average drug price versus the base 
case. Results: Applying solely ERP led to a low average drug price decrease (about 
15% at 10 years), with an apparent equilibrium reached in approximately 7-8 years. 
Price differentials between countries remained substantial over 10 years (about 
30%), suggesting a limited impact of ERP in price convergence. Even if impact 
differed depending on scenarios, all tested scenarios induced price decreases 
and demonstrated the spill-over effects of ERP. Frequent price revisions, itera-
tive price cuts, large country baskets, price calculation methods, genericisation 
impact and prices’ sources were among the most influent parameters on the 
evolution of the drug price over time through ERP-based systems. The repetition 
and combination of various policies generated average price decrease of 92% at 
10 years. ConClusions: This study is the first that quantifies the impact of vari-
ous ERP policies on price erosion. This is a useful tool to support policy decision 
making.
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objeCtives: Cost-utility analysis (CUA) provides valuable information on the 
value of medical technology and is used by many payers to inform coverage and 
the submissions that failed to demonstrate efficacy (52%). Characteristics associ-
ated with a PFR were being a biologic product, having an appropriate comparator, 
showing sufficient clinical evidence and being priced at a similar/lower price than 
the comparator. ConClusions: The presence of patient input was not associated 
with a PFR. The lack of significant association could be attributed to external fac-
tors that are not captured in CADTH’s summary reports and the limited sample 
size of data available. It remains unclear how patient input is integrated into the 
decision making process.
HealtH care use & POlicy studies – disease Management
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objeCtives: This study aims to propose a new geographic administrative organi-
zation of Colombian municipalities for health care management purposes. Rather 
than responding to arbitrary political boundaries, this division should answer to 
health needs and capacities, in order to facilitate the development of targeted poli-
cies to reach universal coverage and improve access to health services. Methods: 
To achieve this, a big database was created: it contains information about different 
health-affecting topics: economic development, socio-cultural background, public 
and transportation services, environmental conditions and health indicators, sup-
ply and demand. These topics were measured with over 70 variables. After that, 
using a principal-component analysis, one or two indicators were created per topic. 
These indicators were used to build clusters that latter allowed the development of 
sanitary regions. Afterwards, another study was made in which people were tracked 
from their residence to the places where they received health services. Then, the 
country was divided into regions reflecting those migration flows. Finally, the study 
mingles both information -the clusters and migration networks- to determine a 
sanitary geography of Colombia. Results: Using the methodology, this study pro-
poses six clustering methodologies that are statistically significant and consistent 
with the reality of Colombia. Also, many networks were proposed, but 5 of them 
represented the national situation closely. Combining these alternatives, the study 
achieves its goal and creates a satisfactory segmentation of the country that is valu-
able for public policy. ConClusions: The proposed categories serve well the needs 
that originated this study and are an appropriate framework for health care manage-
ment purposes. In fact, the Colombian Ministry of Health has used it as an input for 
telemedicine and first infancy projects and health care reform. Its main conclusion 
is that health cannot be worked using political divisions. It is fundamental to use 
supply, demand and context criteria to determine regions useful for policymakers.
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objeCtives: To understand key stakeholder recommendations for the Centers 
for Medicare & Medicaid Services (CMS) regarding the application of its CED pol-
icy, the outcome of national coverage determinations (NCD) in which Medicare 
makes coverage contingent on additional evidence collection through a registry 
or prospective trials, and identify primary concerns with the policy across various 
stakeholders. Methods: The authors analyzed stakeholder comments submit-
ted to CMS during a public comment period on draft updates to the agency’s 2006 
CED policy. The comment period was from November 29, 2012 to January 28, 2013. 
Comments were retrieved from CMS’ Medicare Coverage Database and assessed to 
understand stakeholder positions on issues related to the CED process. Results: 
Of the 27 stakeholders who submitted comments to CMS, over half were from the 
life sciences industry. The majority of stakeholders called for CMS to provide more 
clarity on how the agency plans to address operational issues with CED imple-
mentation. Stakeholders who may be impacted by the issuance of a CED, such as 
manufacturers, are seeking greater transparency from CMS on policies and pro-
cesses for applying CED as well as greater clarity on the parameters for executing 
CED studies. Specifically, 17 stakeholders called on CMS to prohibit CED at the local 
level and restrict its application to the NCD process while 12 stakeholders recom-
mended CMS to provide clear timelines for the duration of CED studies. In addition, 
11 stakeholders requested clarity from CMS on how it intends to collaborate with 
the Food and Drug Administration (FDA) on post-market evidence requirements, 
urging that CED should not duplicate or replace FDA’s authority. ConClusions: 
Going forward, CMS will likely continue to invoke CED with increasing frequency 
and potentially on a broader range of products. Therefore, clearer guidance from 
CMS is critical to ensuring continued stakeholder engagement through Medicare’s 
coverage determination process.
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objeCtives: Analyze factors influencing Erythropoietins (EPO) biosimilars (cop-
ies of patented EPO) (BIOSIM-EPO) uptakes in key global markets. Identify, if pos-
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objeCtives: In the last decade awareness has been raised due to unsafe and 
dangerous devices entering the European market, putting patient safety at stake. 
Consequently, evidence requirements may not be enough to ensure a high-quality 
and safe provision of medical devices in Europe.This research aims at exploring the 
authorization and reimbursement processes and the associated evidence require-
ments comparing four high-impact regions Europe, United States, Australia and 
Canada. Methods: First, we performed a literature search about the authorization 
and reimbursement in the four high-impact regions. Second, seven high-risk medi-
cal devices were chosen as examples and current authorization and reimbursement 
status were assessed. Information was extracted from publicly available summaries, 
from PubMed, and from the clinical trial database (clincialtrial.gov), supplemented by 
the worldwideweb. Results: The evidence required for the authorization and reim-
bursement processes clearly differs in the four high-impact regions. All seven devices 
have been authorized in Europe, three in Australia, one in the United States, and one 
in Canada. Currently none of the seven devices is recommended for reimbursement 
in the four high-impact regions. ConClusions: Looking at the difference in evidence 
requirements, more harmonization, transparency and specific regulations are needed 
worldwide for the authorization and reimbursement of high-risk medical devices to 
ensure a high-quality and safe provision.
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objeCtives: External reference pricing (ERP) is one of most common cost-contain-
ment tools used to reduce prices for in-patent pharmaceuticals in the European 
Union Member States (MS). The objective of this project was to provide an overview 
of ERP systems, both on processes and potential issues related to ERP systems in 31 
European countries (28 EU MS, Iceland, Norway and Switzerland) (performed for the 
EU Commission). Methods: A systematic structured literature review and consulta-
tion of representatives of competent authorities and international organizations were 
conducted to identify and characterize the use of ERP, to describe its impacts on the 
prices of pharmaceuticals and to discuss possible cross-country coordination issues 
in EU MS. Results: All selected countries apply ERP except the UK and Sweden and 
23 countries use ERP as main systematic criterion. ERP is based on legislated pricing 
rules with different levels of accuracy in the majority of European countries using 
ERP. ERP is applied either to all marketed drugs or to specific categories of medicines, 
mainly used for publicly reimbursed medicines. The number of reference countries 
included in the basket varies from 1 to 31. There is a great variation in calculation 
methods used to compute the price; 15 countries use average price, 7 countries use the 
lowest price, and 7 countries use other calculation methods. Among reported limita-
tions of ERP application are reliable sources of price information, price heterogeneity, 
exchange rate volatility, and hidden discounts. Spill-over effects on other countries 
and downward price convergence have often been argued leading to pricing strategies 
from pharmaceutical companies. ConClusions: While ERP is widely used in Europe, 
processes and available price information vary from one country to another that may 
limit ERP application. Moreover, ERP spill-over effect is a major concern of pharmaceu-
tical firms leading to implementation of the so-called “launch sequence strategies”.
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objeCtives: In Korea, the positive list system (PLS) was introduced in 2007 to 
ensure the good value for money in pharmaceutical expenditure. This study aims 
to investigate factors that are most influential in reimbursement decisions under 
the PLS. Methods: To assess the 5 years operations and compare the results 
before and after the PLS, we analyzed the drug prices submitted from the com-
panies, the reimbursement decisions made by Pharmaceutical Benefit Coverage 
Assessment Committee (PBCAC). We extracted data from published evaluation 
reports, PBCAC meeting minutes, and internal documents of Health Insurance 
Review and Assessment Service. Results: Under the PLS, 71% of submitted drugs 
were recommended for reimbursement during January 2007- April 2012. For sub-
missions demonstrated superiority or non-inferiority in clinical benefit, 79% of 
submissions were decided to be reimbursed. However, submissions with inferiority 
or uncertainties in clinical benefit were rejected regardless of the price. Comparing 
the negotiated price under the PLS to the relative price under the negative system, 
the negotiated price was 85% of the relative price. The probability of recommenda-
tion was high when ICER was under the GDP per capita, nevertheless submissions 
with high uncertainty in cost-effectiveness were rejected. Submissions which had 
low uncertainty and products for severe diseases or rare diseases were recom-
mended for reimbursement despite ICER was high. ConClusions: This study 
confirmed clinical benefit was the main driver of the reimbursement decision 
making. Not only clinical benefit and cost-effectiveness but the disease sever-
ity, the uncertainty of evidence and reimbursement in other countries were also 
considered in the reimbursement decision making process. In addition, the drug 
prices were reduced a little after PLS introduced compared to those under the 
negative list system.
reimbursement decisions. Our objective was to evaluate the lag between a drug’s 
FDA approval and the publication of the first published CUA evaluating the prod-
uct. Methods: We used the FDA’s website to identify newly-approved drugs from 
2000-2010 (n= 342). For each drug, we searched the Tufts Medical Center Cost-
Effectiveness Analysis Registry and the NHS Economic Evaluation Database for CUAs 
evaluating the drug for the corresponding FDA-approved indication. We included 
drugs with a corresponding CUA in our dataset. When multiple CUAs for a drug 
were available, we included the CUA with the earliest publication date. We used 
multivariate regression to determine factors associated with time to CUA publica-
tion (years). Independent variables included drug approval year, study funder, i.e., 
whether the CUA was supported by industry, and whether the FDA assigned the 
drug priority review status. Results: One hundred and fifty-six (45.6%) drugs in 
our sample had a corresponding CUA. Average time to CUA publication was 4 years 
(standard deviation 2.3 years). We divided drug approvals into three time inter-
vals; 2000-2002 (mean time to CUA publication= 5.3; SD= 2.4), 2003-2006 (mean= 3.9; 
SD= 2.1) and 2007-2010 (mean= 2.4; SD= 0.97). We found that compared to CUAs for 
drugs approved from 2000-2002, time to CUA publication was 1.5 years shorter for 
drugs approved from 2003-2006 (p< 0.001) and 3 years shorter for drugs approved 
from 2007-2010 (p< 0.0001). Source of study support and FDA priority review sta-
tus were not significantly associated with time to publication ConClusions: For 
FDA-approved drugs with a corresponding CUA, we found a substantial time lag 
between FDA approval and CUA publication, suggesting that decision-makers are 
making important drug coverage and reimbursement decisions without published 
cost-effectiveness evidence available. However, the time to CUA publication appears 
to have declined over time.
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objeCtives: To measure the trend of price level for anti-infective drugs in Tianjin, 
China from 2006 to 2010 using multiple index methods and to explore measurement 
bias induced by index methods and measurement units. Methods: Data were 
extracted from inpatient claims in Tianjin Urban Employee Basic Medical Insurance 
database from 2006 to 2010. Laspeyres, Paasches, Fisher and chained Fisher index 
methods were employed to measure the price level. Price indices were calculated 
both at molecule level (defined by active ingredient) and product level (defined by 
molecule, strength, preparation and manufacturer). Units of quantity and price were 
defined as per DDD (Defined Daily Dose), per milligram of active ingredient, and per 
minimum unit separately to calculate the indices. Results: At product level, 367 
constantly used products (26% of total 1422 products) were included in unchained 
indices and 1041 products (73% of total products) were included in chained Fisher 
indices. The results of multiple indices consistently indicated that the price level 
decreased and the decreasing range indicated by different index methods were 
from 16% (Laspeyres-unit index at molecule level) to 27% (Laspeyres-DDD index at 
product level). The price indices at molecule level decreased slower than the coun-
terparts at product level (22% vs. 25% in chained Fisher-DDD index). At molecule 
level, price indices based on per DDD decreased faster than per mg and per unit 
(22%, 21% and 18% in chained Fisher). Laspeyres indices decreased slower than 
Paasches at molecule level while the contrary was the case at product level. The 
results from chained Fisher and unchained counterparts were similar (25% vs. 26% 
at product level). ConClusions: The price level of anti-infective drugs decreased 
heavily in Tianjin, China. The chained indices were similar to the unchained coun-
terparts which suggested that the price of newer and older products decreased at 
similar rate.
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objeCtives: To establish performance evaluation model of the Essential Medicine 
System in China based on Data Envelopment Analysis(DEA), evaluate the relative 
efficiency of essential medicines system and analysis the main problem and impact 
factors on it. Methods: 15 counties in Sichuan province were selected by stratified 
sampling as Decision Making Units(DMUs); for each county, 30% primary health 
care facilities, totally 284 facilities were involved as sample. Questionnaire survey 
was conducted to collect data of input and output indicators in 2010 and 2011 from 
sample facilities. 3 input indicators and 4 output indicators were set based on lit-
erature review, WHO’s National Drug Policies Monitoring Indicators and experiential 
principle of DEA. Excel 2007 was used to encode data, DEAP 2.1 software was used 
to conduct CRS - CCR and VRS - BCC Data Envelopment Analysis, SPSS16.0 was used 
to conduct T-test and multiple linear regression analysis to exam the statistic dif-
ference between 2010 and 2011, and the influencing factors of efficiency. Results: 
For input indicators, the average special funds of Essential Medicine System(x1) in 
15 counties was raised from 0.52 million US$ in 2010 to 0.69 million US$ in 2011
；the average number of essential medicines(x2) and drug delivery companies(x3) 
raised as well. For output indicators, average outpatient cost per visit(y1) and inpa-
tient cost per admission(y2) decreased, while the outpatient visit times(y3) and 
discharge numbers(y4) kept no increasing as expected. The overall efficiency of 
Essential Medicines System in Sichuan province in two years were in relatively 
high level(0.908 in 2010 and 0.832 in 2011). Analysis on technical efficiency, scale 
efficiency, and return to scale showed the main existing problem was insufficient 
utilization of input health care resource. ConClusions: The effectiveness of imple-
mentation of Nation Essential Medicine System has been displayed, but health 
care resources should be adjusted and utilized rationally to improve the overall 
efficiency.
